Development of RAD51 degraders for ovarian cancer treatment PARP inhibitor drugs have had a major impact on the clinical treatment of ovarian cancer in recent years, but they do not work in all patients. Many tumors have genetic mutations that make the tumor unable to repair damage to its DNA. PARP inhibitors exploit this fact […]
Read More